The systemic sclerodermas and related disorders

Textbook of Pediatric Rheumatology

Volumn , Issue , 2005, Pages 442-471

  Zulian, Francesco ^c   Cassidy, James T ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39749202624     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0246-8.50025-5     Document Type: Chapter

References (371)

1. Lewin G, Heller J Die Sclerodermie 1895, August Hirschwald, Berlin.
2. Goodman H A case of scleroderma diffusa in a girl, nine years of age; with a review of the literature. J Cutan Pathol 1918, 36:210.
3. Jaffe MO, Winkelmann RK Generalized scleroderma in children. Acrosclerotic type. Arch Dermatol 1961, 83:402.
4. Kass H, Hanson V, Patrick J Scleroderma in childhood. J Pediatr 1966, 68:243.
5. Tuffanelli DL, Winkelmann RK Systemic scleroderma. A clinical study of 727 cases. Arch Dermatol 1961, 84:359.
6. Martini G, Foeldvari I, Russo R, et al. Systemic scleroderma syndromes in children: clinical and immunological characteristics of 181 patients. Arthritis Rheum 2003, 48(Suppl):S512.
7. Zulian F, De Oliveira SKF, Lehman TH, et al. Juvenile localized scleroderma: clinical epidemiological features of 688 patients. Arthritis Rheum 2003, 48:S649.
8. Kraus ET Zur pathogenese der diffusen Sklerodermie. Zugleich ein Beitrag zur Pathologie der Epithelkörperchen. Virchows Archiv (Pathol Anat) 1924, 253:710.
9. Matsui S Anatomie pathologique et pathogénic de la scléropdermie géneralisée. Presse Med 1924, 32:142.
10. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428-440.
11. Rodnan GP When is scleroderma not scleroderma? The differential diagnosis of progressive systemic sclerosis. Bull Rheum Dis 1981, 31:7-10.
12. Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000, 43:444-451.
13. Slobodin G, Rosner I, Rozenbaum M, et al. Systemic sclerosis sine scleroderma: is it always the same disease? Report of three patients and discussion. Rheumatol Int 2002, 22:170-172.
14. Kurland LT, Hauser WA, Ferguson RH, et al. Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969, 44:649-663.
15. Caperton EM, Hathaway DE Scleroderma with eosinophilia and hypergammaglobulinemia: the Shulman syndrome. Arthritis Rheum 1975, 18:391.
16. Medsger TA, Masi AT Epidemiology of progressive systemic sclerosis. Clin Rheum Dis 1979, 5:15.
17. Shinkai H Epidemiology of progressive systemic sclerosis in Japan. Systemic Sclerosis (Scleroderma) 1985, 79. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
18. Asboe-Hansen G Epidemiology of progressive systemic sclerosis in Denmark. Systemic Sclerosis (Scleroderma) 1985, 78. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
19. Giordano M, Valentini G, Ara M, et al. Epidemiology of progressive systemic sclerosis in Italy. Systemic Sclerosis (Scleroderma) 1985, 72-77. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
20. Barnett AJ Epidemiology of systemic sclerosis (scleroderma) in Australia. Systemic Sclerosis (Scleroderma) 1985, 82. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
21. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997, 40:734-742.
22. Mayes MD Scleroderma epidemiology. Rheum Dis Clin North Am 2003, 29:239-254.
23. Mayes MD, Lacey JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival,. and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
24. Tuffanelli DL, LaPerriere R Connective tissue diseases. Pediatr Clin North Am 1971, 18:925-951.
25. Medsger TA, Masi AT Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 1971, 74:714-721.
26. Hanson V Dermatomyositis, scleroderma, and polyarteritis nodosa. Clin Rheum Dis 1976, 2:445.
27. Komreich HK, King KK, Bernstein BH, et al. Scleroderma in childhood. Arthritis Rheum 1977, 20:343-350.
28. Medsger TA Epidemiology of systemic sclerosis. Clin Dermatol 1994, 12:207-216.
29. Emery H Pediatric scleroderma. Semin Cutan Med Surg 1998, 17:41-47.
30. Black CM Scleroderma in children. Adv Exp Med Biol 1999, 455:35-48.
31. Sato S, Ishida W, Takehara K A case of juvenile systemic sclerosis with disease onset at six months old. Clin Rheumatol 2003, 22:162-163.
32. Cassidy JT, Sullivan DB, Dabich L, et al. Scleroderma in children. Arthritis Rheum 1977, 20:351-354.
33. Foeldvari I Scleroderma in children. Curr Opin Rheumatol 2002, 14:699-703.
34. Murray KJ, Laxer RM Scleroderma in children and adolescents. Rheum Dis Clin North Am 2002, 28:603-624.
35. Kennedy WP Cardiac death from progressive systemic scleroderma in a child. Can Med Assoc J 1964, 90:33.
36. Mukherjee SK, Lahiri K, Sen MK Scleroderma in a boy of nine. J Indian Med Assoc 1966, 47:132-135.
37. Velayos EE, Cohen BS Progressive systemic sclerosis. Diagnosis at the age of 4 years. Am J Dis Child 1972, 123:57-60.
38. Szymanska-Jagiello W, Rondio H, Jakubowska K Changes in the locomotor system in progressive systemic sclerosis in children. Mater Med Pol 1972, 4:201-209.
39. Goel KM, Shanks RA Scleroderma in childhood. Report of 5 cases. Arch Dis Child 1974, 49:861-866.
40. Ansell BM, Nasseh GA, Bywaters EG Scleroderma in childhood. Ann Rheum Dis 1976, 35:189-197.
41. Gray RG, Altman RD Progressive systemic sclerosis in a family: case report of a mother and son and review of the literature. Arthritis Rheum 1977, 20:35-41.
42. Schlesinger M, Schaller JG Progressive systemic sclerosis of childhood. Arthritis Rheum 1981, 24(Suppl):S104.
43. Girouard M, Pare C, Camerlain M Juvenile scleroderma. Union Med Can 1982, 111:546-551.
44. Spencer-Green G, Schlesinger M, Bove KE, et al. Nailfold capillary abnormalities in childhood rheumatic diseases. J Pediatr 1983, 102:341-346.
45. Larrègue M, Canuel C, Bazex J, et al. [Systemic scleroderma in children. Apropos of 5 cases. A review of the literature). Ann Dermatol Venereol 1983, 110:317-326.
46. Burge SM, Ryan TJ, Dawber RP Juvenile onset systemic sclerosis. J R Soc Med 1984, 77:793-794.
47. Suarez-Almazor ME, Catoggio LJ, Maldonado-Cocco JA, et al. Juvenile progressive systemic sclerosis: clinical and serologic findings. Arthritis Rheum 1985, 28:699-702.
48. Lababidi HM, Nasr FW, Khatib Z Juvenile progressive systemic sclerosis: report of five cases. J Rheumatol 1991, 18:885-888.
49. Martinez-Cordero E, Fonseca MC, Aquilar Leon DE, et al. Juvenile systemic sclerosis. J Rheumatol 1993, 20:405-407.
50. Vancheeswaran R, Black CM, David J, et al. Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum 1996, 39:1041-1049.
51. Steen VD, Oddis CV, Conte CG, et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997, 40:441-445.
52. Jimenez SA, Derk CT Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004, 140:37-50.
53. Fleischmajer R, Perlish JS, Reeves JR Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977, 20:975-984.
54. Roumm AD, Whiteside TL, Medsger TA, et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27:645-653.
55. Abraham DJ, Shiwen X, Black CM, et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000, 275:15220-15225.
56. Varga J, Rosenbloom J, Jimenez SA Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987, 247:597-604.
57. Kikuchi K, Kadono T, Furue M, et al. Tissue inhibitor of metalloproteinase 1 (TTMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997, 108:281-284.
58. Ihn H, Yamane K, Kubo M, et al. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001, 44:474-480.
59. Kubo M, Ihn H, Yamane K, et al. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001, 44:731-734.
60. Ohtsuka T, Yamakage A, Yamazaki S The polymorphism of transforming growth factor-beta 1 gene in Japanese patients with systemic sclerosis. Br J Dermatol 2002, 147:458-463.
61. Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001, 108:241-250.
62. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000, 27:149-154.
63. Gore-Hyer E, Pannu J, Smith EA, et al. Selective stimulation of collagen synthesis in the presence of costimulatory insulin signaling by connective tissue growth factor in scleroderma fibroblasts. Arthritis Rheum 2003, 48:798-806.
64. Needleman BW, Wigley FM, Stair RW lnterleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35:67-72.
65. Hasegawa M, Sato S, Ihn H, et al. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxf) 1999, 38:612-617.
66. Atamas SP, Yurovsky VV, Wise R, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42:1168-1178.
67. Sato S, Hanakawa H, Hasegawa M, et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000, 27:2838-2842.
68. Shahin AA, Anwar S, Elawar AH, et al. Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and impaired left ventricular diastolic function. Rheumatol Int 2000, 20:21-24.
69. Komura K, Sato S, Fujimoto M, et al. Elevated levels of circulating CD44 in patients with systemic sclerosis: association with a milder subset. Rheumatology (OxD 2002, 41:1149-1154.
70. Sato H, Lagan AL, Alexopoulou C, et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 2004, 50:558-564.
71. Hasegawa M, Sato S, Takehara K Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-lalpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999, 117:159-165.
72. Galindo M, Santiago B, Rivero M, et al. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001, 44:1382-1386.
73. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001, 44:2665-2678.
74. Furuse S, Fujii H, Kaburagi Y, et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 2003, 30:1524-1528.
75. Huffstutter JE, DeLustro FA, LeRoy EC Cellular immunity to collagen and laminin in scleroderma. Arthritis Rheum 1985, 28:775-780.
76. Irani AM, Gruber BL, Kaufman LD, et al. Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation. Arthritis Rheum 1992, 35:933-939.
77. Kahaleh MB, Osborn I, LeRoy EC Increased factor VHI/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981, 94:482-484.
78. Woolf AD, Wakerley G, Wallington TB, et al. Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis 1987, 46:441-447.
79. Matucci-Cerinic M, Pignone A, Lotti T, et al. Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? J Rheumatol 1990, 17:328-330.
80. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785-792.
81. Fries JF The microvascular pathogenesis of scleroderma: an hypothesis. Ann Intern Med 1979, 91:788-789.
82. Salojin KV, Le Tonqueze M, Saraux A, et al. Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 1997, 102:178-185.
83. Pignone A, Scaletti C, Matucci-Cerinic M, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998, 16:527-532.
84. Gruschwitz MS, Hornstein OP, von Den DP Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995, 38:184-189.
85. Shimada Y, Hasegawa M, Takehara K, et al. Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis. Clin Exp Immunol 2001, 124:474-479.
86. Gruschwitz M, von Den DP, Kellner I, et al. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992, 27:169-177.
87. Shi-Wen X, Panesar M, Vancheeswaran R, et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthritis Rheum 1994, 37:1689-1697.
88. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993, 61:239-246.
89. Kuroda K, Okamoto O, Shinkai H Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-betal, interleukin-4, and matrix collagen. J Invest Dermatol 1999, 112:706-710.
90. Jelaska A, Arakawa M, Broketa G, et al. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996, 39:1338-1346.
91. Lovell CK, Nicholls AC, Duance VC, et al. Characterization of dermal collagen in systemic sclerosis. Br J Dermatol 1979, 100:359-369.
92. Brady AH Collagenase in scleroderma. J Clin invest 1975, 56:1175-1180.
93. Uitto J, Bauer EA, Eisen AZ Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 1979, 64:921-930.
94. Peltonen L, Palotie A, Myllyla R, et al. Collagen biosynthesis in systemic scleroderma: regulation of posttranslational modifications and synthesis of procollagen in cultured fibroblasts. J Invest Dermatol 1985, 84:14-18.
95. Blumenkrantz N, Ashoe-Hanson G Subhydroxylated collagen in scleroderma. Acta Derm Venereol 1978, 58:359-361.
96. Santiago B, Galindo M, Rivero M, et al. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001, 44:1667-1676.
97. Burge KM, Perry HO, Stickler GB "Familial" scleroderma. Arch Dermatol 1969, 99:681-687.
98. De Keyser F, Peene I, Joos R, et al. Occurrence of scleroderma in monozygotic twins. J Rheumatol 2000, 27:2267-2269.
99. Englert H, Small-McMahon J, Chambers P, et al. Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999, 29:36-41.
100. Clements PJ, Opelz G, Terasaki PI, et al. Association of HLA antigen a9 with progressive systemic sclerosis (scleroderma). Tissue Antigens 1978, 11:357-361.
101. Van der Meulen, Van der Voort-Beelen JM, D'Amaro J, et al. HLA-B8 in Raynaud's phenomenon. Tissue Antigens 1980, 15:81.
102. Kallenberg CG, Van der Voort-Beelen JM, D'Amaro J, et al. Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol 1981, 43:478-485.
103. Lynch CJ, Singh G, Whiteside TL, et al. Histocompatibility antigens in progressive systemic sclerosis (PSS: scleroderma). J Clin Immunol 1982, 2:314-318.
104. Gladman DD, Keystone EC, Baron M, et al. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum 1981, 24:854-856.
105. Black CM, Welsh KI, Maddison PJ, et al. HLA antigens in scleroderma. Systemic Sclerosis (Scleroderma) 1985, 84-88. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
106. Whiteside TL, Medsger TA, Rodnan G Studies of HLA antigens in progressive systemic sclerosis. Systemic Sclerosis (Scleroderma) 1985, 89. Gower Medical, New York. C.M. Black, A.R. Meyers (Eds.).
107. Fox RI, Kang HI Genetic and environmental factors in systemic sclerosis. Curr Opin Rheumatol 1992, 4:857-861.
108. Lambert NC, Pang JM, Hermes HM, et al. HLA-DRB1 genes in risk of systemic sclerosis in women, and potential modulation of risk by microchimerism from pregnancy. Arthritis Rheum 2003, 48(Suppl):S356.
109. Megli FM, Mattiazzi M, Di Tullio T, et al. Annexin V binding perturbs the cardiolipin fluidity gradient in isolated mitochondria. Can it affect mitochondrial function? Biochemistry 2000, 39:5534-5542.
110. Artlett CM, O'Hanlon TP, Lopez AM, et al. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum 2003, 48:2567-2572.
111. Burastero SE, Galbiati S, Vassallo A, et al. Cellular microchimerism as a lifelong physiologic status in parous women: an immunologic basis for its amplification in patients with systemic sclerosis. Arthritis Rheum 2003, 48:1109-1116.
112. Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998, 351:559-562.
113. Sontheimer RD A portable digital microphotography unit for rapid documentation of periungual nailfold capillary changes in autoimmune connective tissue diseases. J Rheumatol 2004, 31:539-544.
114. Ohtsuka T, Miyamoto Y, Yamakage A, et al. Quantitative analysis of microchimerism in systemic sclerosis skin tissue. Arch Dermatol Res 2001, 293:387-391.
115. Artlett CM, Smith JB, Jimenez SA Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998, 338:1186-1191.
116. Dabich L, Sullivan DB, Cassidy JT Scleroderma in the child. J Pediatr 1974, 85:770-775.
117. Valentini G, Medsger TA, Silman AJ, et al. The assessment of the patient with systemic sclerosis. Introduction. Clin Exp Rheumatol 2003, 21(Suppl 29):S2-S4.
118. Maricq HR, Spencer-Green G, LeRoy EC Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 1976, 61:862-870.
119. Jacobs MJ, Breslau PJ, Slaaf DW, et al. Nomenclature of Raynaud's phenomenon: a capillary microscopic and hemorheologic study. Surgery 1987, 101:136-145.
120. Patterson JW Pterygium inversum unguis-like changes in scleroderma. Report of four cases. Arch Dermatol 1977, 113:1429-1430.
121. Moore CP, Willkens RF The subcutaneous nodule, Its significance in the diagnosis of rheumatic disease. Semin Arthritis Rheum 1977, 7:63-79.
122. Raynaud M De l'asphyxie locale et de la gangrene symetrique des extremities 1862, L Leclerc, Libraire-Editeur, Paris.
123. Raynaud M On local asphyxia and symmetrical gangrene of the extremities (1862). Arch Gen Med 1874, 1:189.
124. Yarom A, Levinson JE Vasculopathy in scleroderma. Vasculopathies in Childhood 1988, 243. PSG Publishing, Littleton, MA. R.V. Hicks (Ed.).
125. Duffy CM, Laxer RM, Lee P, et al. Raynaud syndrome in childhood. J Pediatr 1989, 114:73-78.
126. Follansbee WP, Curtiss EI, Medsger TA, et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984, 310:142-148.
127. Allen EV, Brown GE Raynaud's disease: A critical review of minimal requisites for diagnosis. Am J Med Sci 1932, 183:187.
128. Jones GT, Herrick AL, Woodham SE, et al. Occurrence of Raynaud's phenomenon in children ages 12-15 years: prevalence and association with other common symptoms. Arthritis Rheum 2003, 48:3518-3521.
129. Jung LK, Dent PB Prognostic significance of Raynaud's phenomenon in children. Clin Pediatr (Phila) 1983, 22:22-25.
130. Nigrovic PA, Fuhlbrigge RC, Sundel RP Raynaud's phenomenon in children: a retrospective review ot 123 patients. Pediatrics 2003, 111:715-721.
131. Harper FE, Maricq HR, Turner RE, et al. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 1982, 72:883-888.
132. Del Bianco E, Magini B, Muscarella G, et al. Raynaud's phenomenon (primary or secondary to systemic sclerosis), The usefulness of laser-Doppler flowmetry in the diagnosis. Int Angiol 2001, 20:307-313.
133. Dabich L, Bookstein JJ, Zweifler A, et al. Digital arteries in patients with scleroderma. Arteriography and plethysmographic study. Arch Intern Med 1972, 130:708-714.
134. LeRoy EC, Downey JA, Cannon PJ Skin capillary blood flow in scleroderma. J Clin Invest 1971, 50:930-939.
135. Winkelmann RK, Goldyne ME, Linscheid RL Influence of cold on catecholamine response of vascular smooth muscle strips from resistance vessels of scleroderma skin. Angiology 1977, 28:330-339.
136. Winkelmann RK, Goldyne ME, Linscheid RL Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol 1976, 95:51-56.
137. Kallenberg CG, Vellenga E, Wouda AA, et al. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol 1982, 9:878-884.
138. Majerus PW Arachidonate metabolism in vascular disorders. J Clin Invest 1983, 72:1521-1525.
139. Crocq C De I' "acrocyanose.". Semaine Med 1896, 16:208.
140. Lewis T, Landis EM Observations upon the vascular mechanism in acrocyanosis. Heart 1930, 15:230.
141. Stern ES The aetiology and pathology of acrocyanosis. Br J Dermatol Syphilis 1937, 49:100.
142. Peacock JH Vasodilatation in the human hand. Observations on primary Raynaud's disease and acrocyanosis of the upper extremities. Clin Sci 1957, 17:575.
143. Peacock JH A comparative study of the digital cutaneous temperatures and hand blood flows in the normal hand, primary Raynaud's disease and primary acrocyanosis. Clin Sci 1959, 18:25.
144. Sivula A Vascular reactions in acrocyanosis. Angiology 1966, 17:269-274.
145. Goette DK Chilblains (perniosis). J Am Acad Dermatol 1990, 23:257-262.
146. Clements PJ, Furst DE, Campion DS, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 1978, 21:62-71.
147. Ortiz-Alvarez O, Cabral D, Prendiville JS, et al. Intestinal pseudo-obstruction as an initial presentation of systemic sclerosis in two children. Br J Rheumatol 1997, 36:280-284.
148. Wang SJ, Lan JL, Chen DY, et al. Colonic transit disorders in systemic sclerosis. Clin Rheumatol 2001, 20:251-254.
149. Quartier P, Bonnet D, Fournet JC, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. J Rheumatol 2002, 29:1767-1773.
150. Steen V The heart in systemic sclerosis. Curr Rheumatol Rep 2004, 6:137-140.
151. Follansbee WP, Zerbe TR, Medsger TA Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993, 125:194-203.
152. Gupta MP, Zoneraich S, Zeitlin W, et al. Scleroderma heart disease with slow flow velocity in coronary arteries. Chest 1975, 67:116-119.
153. Eid NS, Buchino JJ, Schikler KN Pulmonary manifestations of rheumatic diseases. Pediatr Pulmonol Suppl 1999, 18:91-92.
154. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003, 62:146-150.
155. Hill CL, Nguyen AM, Roder D, et al. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003, 62:728-731.
156. Denton CP, Black CM Combination therapies for systemic sclerosis. Springer Semin Immunopathol 2001, 23:109-129.
157. Furst DE, Davis JA, Clements PJ, et al. Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. Arthritis Rheum 1981, 24:1403-1408.
158. Fahey PJ, Utell MJ, Condemi JJ, et al. Raynaud's phenomenon of the lung. Am J Med 1984, 76:263-269.
159. Veselý R, Vargová V, Ravelli A, et al. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. J Rheumatol 2004, 31:795-800.
160. Rhew EY, Barr WG Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep 2004, 6:129-136.
161. Medsger TA, Masi AT Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973, 26:647-660.
162. Cannon PJ, Hassar M, Case DB, et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 1974, 53:1-46.
163. Oliver JA, Cannon PJ The kidney in scleroderma. Nephron 1977, 18:141-150.
164. LeRoy EC, Fleischmann RM The management of renal scleroderma: experience with dialysis, nephrectomy and transplantation. Am J Med 1978, 64:974-978.
165. Whitman HH, Case DB, Laragh JH, et al. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum 1982, 25:241-248.
166. Burke MJ, Carty JE Trigeminal neuropathy as the presenting symptom of systemic sclerosis. Postgrad Med J 1979, 55:423-425.
167. Teasdall RD, Frayha RA, Shulman LE Cranial nerve involvement in systemic-sclerosis (scleroderma): a report of 10 cases. Medicine (Baltimore) 1980, 59:149-159.
168. Farrell DA, Medsger TA Trigeminal neuropathy in progressive systemic sclerosis. Am J Med 1982, 73:57-62.
169. Lee P, Bruni J, Sukenik S Neurological manifestations in systemic sclerosis (scleroderma). J Rheumatol 1984, 11:480-483.
170. Dahlgaard T, Nielsen VK, Kristensen JK Vibratory perception in patients with generalized scleroderma. Acta Derm Venereol 1980, 60:119-122.
171. Estey E, Lieberman A, Pinto R, et al. Cerebral arteritis in scleroderma. Stroke 1979, 10:595-597.
172. Alarcon-Segovia D, Ibanez G, Hernandez-Ortiz J, et al. Sjögren's syndrome in progressive systemic sclerosis (scleroderma). Am J Med 1974, 57:78-85.
173. Fleischmajer R, Perlish JS, West WP Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 1977, 113:1661-1666.
174. Rodnan GP, Myerowitz RL, Justh GO Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980, 59:393-408.
175. Claman HN Mast cells and fibrosis. The relevance to scleroderma. Rheum Dis Clin North Am 1990, 16:141-151.
176. Braun-Falco O Über das Verhalten der interfibrillaren Grundsubstanz bei Sklerodermia. Dermatol Wochenschr 1957, 136. 1085 [cited by Rodnan GP: Progressive systemic sclerosis: clinical features and pathogenesis of cutaneous involvement (scleroderma). Clin Rheum Dis 5: 49, 1979].
177. Rodnan GP, Lipinski E, Luksick J Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979, 22:130-140.
178. Hayes RL, Rodnan GP The ultrastructure of skin in progressive systemic sclerosis (scleroderma). I. Dermal collagen fibers. Am J Pathol 1971, 63:433-442.
179. Rodnan GP, Medsger TA Musculoskeletal involvement in progressive systemic sclerosis (scleroderma). Bull Rheum Dis 1966, 17:419.
180. Clark JA, Winkelmann RK, Ward LE Serologic alterations in scleroderma and sclerodermatomyositis. Mayo Clin Proc 1971, 46:104-107.
181. Medsger TA, Rodnan GP, Moossy J, et al. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968, 11:554-568.
182. Lindamood M, Mills D, Steigerwald J Skeletal muscle abnormalities in progressive systemic sclerosis. Arthritis Rheum 1976, 19:807.
183. Bulkley BH Progressive systemic sclerosis: Cardiac involvement. Clin Rheum Dis 1979, 5:131.
184. Russell ML, Friesen D, Henderson RD, et al. Ultrastructure of the esophagus in scleroderma. Arthritis Rheum 1982, 25:1117-1123.
185. Smith JW, Clements PJ, Levisman J, et al. Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies. Am J Med 1979, 66:28-33.
186. Young RH, Mark GJ Pulmonary vascular changes in scleroderma. Am J Med 1978, 64:998-1004.
187. Lapenas D, Rodnan GP, Cavallo T Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma). Am J Pathol 1978, 91:243-258.
188. McGiven AR, De Boer WG, Barnett AT Renal immune deposits in scleroderma. Pathology 1971, 3:145-150.
189. Gerber MA Imrnunohistochemical findings in the renal vascular lesions of progressive systemic sclerosis. Hum Pathol 1975, 6:343-347.
190. Jarmolych J, Daoud AS, Landau J, et al. Aortic media explants. Cell proliferation and production of mucopolysaccharides, collagen, and elastic tissue. Exp Mol Pathol 1968, 9:171-188.
191. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590.
192. LeRoy EC, Medsger TA Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
193. Falcini F, Trapani S, Taccetti G, et al. [Systemic sclerosis in childhood]. Pediatr Med Chir 1990, 12:593-599.
194. Ansell BM, Falcini F, Woo P Scleroderma in childhood. Clin Dermatol 1994, 12:299-307.
195. Martini A Juvenile systemic scleroderma. Curr Rheumatol Rep 2001, 3:387-390.
196. Athreya BH Juvenile scleroderma. Curr Opin Rheumatol 2002, 14:553-561.
197. Penas PF, Jones-Caballero M, Aragues M, et al. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol 2002, 138:924-934.
198. Dall'Amico R, Rossetti F, Zulian F, et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997, 97:848-854.
199. Clements PJ, Furst DE, Ho W, et al. Progressive systemic sclerosis-like disease following bone marrow traasplantation. Systemic Sclerosis (Scleroderma) 1985, 376-381. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
200. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001, 23:383-393.
201. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000, 356:1000-1001.
202. Owens GR, Medsger TA Systemic sclerosis secondary to occupational exposure. Am J Med 1988, 85:114-116.
203. Selikoff IJ, Hammond EC Toxicity of vinyl chloride polyvinyl chloride. Ann N Y Acad Sci 1975, 246:1.
204. Cohen IS, Mosher MB, O'Keefe EJ, et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 1973, 107:553-555.
205. Luna MA, Bedrossian CW, Lichtiger B, et al. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol 1972, 58:501-510.
206. Finch WR, Buckingham RB, Rodnan GP, et al. Scleroderma induced by bleomycin. Systemic Sclerosis (Scleroderma) 1985, 114-121. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
207. Palestine RF, Millns JL, Spigel GT, et al. Skin manifestations of pentazocine abuse. J Am Acad Dermatol 1980, 2:47-55.
208. Kilbourne EM, Rigau-Perez JG, Heath CW, et al. Clinical epidemiology of toxic-oil syndrome. Manifestations of a new illness. N Engl J Med 1983, 309:1408-1414.
209. Alonso-Ruiz A, Zea-Mendoza AC, Salazar-Vallinas JM, et al. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthritis Rheum 1986, 15:200-212.
210. Diaz-Perez JL, Zubizarreta J, Gardeazabal J, et al. [Familial eosinophilic fascitis induced by toxic oil]. Med Cutan Ibero Lat Am 1988, 16:51-58.
211. Izquierdo M, Mateo I, Rodrigo M, et al. Chronic juvenile toxic epidemic syndrome. Ann Rheum Dis 1985, 44:98-103.
212. Miyjoshi K, Shiragami H, Yoshida K Adjuvant disease of man. Clin Immunol (Tokyo) 1973, 5:785.
213. Kumagai Y, Shiokawa Y, Medsger TA, et al. Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum 1984, 27:1-12.
214. Santavirta S, Konttinen YT, Bergroth V, et al. Aggressive granulomatous lesions associated with hip arthroplasty. Immunopathological studies. J Bone Joint Surg Am 1990, 72:252-258.
215. Bridges AJ, Vasey FB Silicone breast implants. History, safety, and potential complications. Arch Intern Med 1993, 153:2638-2644.
216. Wolfe F "Silicone related symptoms" are common in patients with fibromyalgia: no evidence for a new disease. J Rheumatol 1999, 26:1172-1175.
217. Wolfe F, Anderson J Silicone filled breast implants and the risk of fibromyalgia and rheumatoid arthritis [published erratum appears in J Rheumatol 27: 825, 2000]. J Rheumatol 1999, 26:2025-2028.
218. Kornreich HK, Shaw KN, Koch R, et al. Phenylketonuria and scleroderma. J Pediatr 1968, 73:571-575.
219. Lasser AE, Schultz BC, Beaff D, et al. Phenylketonuria and scleroderma. Arch Dermatol 1978, 114:1215-1217.
220. Coskun T, Ozalp I, Kale G, et al. Scleroderma-like skin lesions in two patients with phenylketonuria. Eur J Pediatr 1990, 150:109-110.
221. Nova MP, Kaufman M, Halperin A Scleroderma-like skin indurations in a child with phenylketonuria: a clinicopathologic correlation and review of the literature. J Am Acad Dermatol 1992, 26:329-333.
222. Nishimura N, Okamtoto M, Yasui M, et al. Intermediary metabolism of phenylalanine and tyrosine in diffuse collagen diseases. II. Influences on the low phenylalanine and tyrosine diet upon patients with collagen diseases. Arch Dermatol 1959, 80:466.
223. Drummond KN, Michael AF, Good RA Tryptophan metabolism in a patient with phenylketonuria and scleroderma: a proposed explanation of the indole defect in phenylketonuria. Can Med Assoc J 1966, 94:834-838.
224. Villee DB, Nichols G, Talbot NB Metabolic studies in two boys with classical progeria. Pediatrics 1969, 43:207-216.
225. Fleischmajer R, Pollock JL Progressive systemic sclerosis: Pseudoscleroderma. Clin Rheum Dis 1979, 5:243.
226. Jansen T, Romiti R Progeria infantum (Hutchinson-Gilford syndrome) associated with scleroderma-like lesions and acro-osteolysis: a case report and brief review of the literature. Pediatr Dermatol 2000, 17:282-285.
227. Epstein CJ, Martin GM, Schultz AL, et al. Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 1966, 45:177-221.
228. Bauer EA, Uitto J, Tan EM, et al. Werner's syndrome. Evidence for preferential regional expression of a generalized mesenchymal cell defect. Arch Dermatol 1988, 124:90-101.
229. Rocco VK, Hurd ER Scleroderma and scleroderma-like disorders. Semin Arthritis Rheum 1986, 16:22-69.
230. Rosenberg HS, Stenback WA, Spjut HJ The fibromatoses of infancy and childhood. Perspect Pediatr Pathol 1978, 4:269-348.
231. Falanga V Fibrosing conditions in childhood. Adv Dermatol 1991, 6:145-158.
232. Young EM, Barr RJ Sclerosing dermatoses. J Cutun Pathol 1985, 12:426-441.
233. Ormond JK Idiopathic retroperitoneal fibrosis: a discussion of the etiology. J Urol 1965, 94:385-390.
234. Marshall AJ, Baddeley H, Barritt DW, et al. Practolol peritonitis. A study of 16 cases and a survey of small bowel function in patients taking beta adrenergic blockers. Q J Med 1977, 46:135-149.
235. Stout Al' The fibromatoses. Clin Orthop 1961, 19:11.
236. Allen PW The fibromatoses: a clinicopathologic classification based on 140 cases. Am. I Surg Pathol 1977, 1:255-270.
237. Enzinger EM, Weiss SW Soft Tissue Tumors 1983, CV Mosby, St. Louis.
238. Greenberg LM, Geppert C, Worthen HG, et al. Scleredema "adultorum" in children. Report of three cases with histochemical study and review of the world literature. Pediatrics 1963, 32:1044.
239. Venencie PY, Powell FC, Su WP, et al. Scleredema: a review of thirty-three cases. J Am Acad Dermatol 1984, 11:128-134.
240. Grgic A, Rosenbloom AL, Weber FT, et al. Joint contracture-common manifestation of childhood diabetes mellitus. J Pediatr 1976, 88:584-588.
241. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1979, 67:277-286.
242. Doyle JA, Friedman SJ Porphyria and scleroderma: a clinical and laboratory review of 12 patients. Australas J Dermatol 1983, 24:109-114.
243. Doyle JA, Connolly SM, Hoagland HC Hematologic disease in scleroderma syndromes. Acta Derm Venereol 1985, 65:521-525.
244. Giordano M, Ara M, Valentini G, et al. Presence of eosinophilia in progressive systemic sclerosis and localized scleroderma. Arch Dermatol Res 1981, 271:411-417.
245. Rodnan GP, Medsger TA The rheumatic manifestations of progressive systemic sclerosis (scleroderma). Clin Orthop 1968, 57:81-93.
246. Gladman DD, Gordon DA, Urowitz MB, et al. Pericardial fluid analysis in scleroderma (systemic sclerosis). Am J Med 1976, 60:1064-1068.
247. Steen VD, Powell DL, Medsger TA Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31:196-203.
248. Kikuchi M, Inagaki T Bibliographical study of the concurrent existence of anticentromere and antitopoisomerase I antibodies. Clin Rheumatol 2000, 19:435-441.
249. Sato S, Hamaguchi Y, Hasegawa M, et al. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxf) 2001, 40:1135-1140.
250. Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991, 338:661-662.
251. Bunn CC, Denton CP, Shi-Wen X, et al. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998, 37:15-20.
252. MacGregor AJ, Davrashvili J, Knight C, et al. Early pulmonary hypertension in systemic sclerosis: risk of progression and consequences for survival. Arthritis Rheum 1996, 39(Suppl):S151.
253. Hossny E, Hady HA, Mabrouk R Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. Pediatr Allergy Immunol 2000, 11:250-255.
254. Weiner ES, Earnshaw WC, Senecal JL, et al. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988, 31:378-385.
255. Fregeau DR, Leung PS, Coppel RL, et al. Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum 1988, 31:386-392.
256. Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992, 35:1211-1217.
257. Khanna D, Aggarwal A, Bhakuni DS, et al. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J Rheumatol 2003, 30:1248-1252.
258. Armstrong GP, Whalley GA, Doughty RN, et al. Left ventricular function in scleroderma. Br J Rheumatol 1996, 35:983-988.
259. Clements PJ, Furst DE, Cabeen W, et al. The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med 1981, 71:38-46.
260. Alexander EL, Firestein GS, Weiss JL, et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 1986, 105:661-668.
261. Gottdiener JS, Moutsopoulos HM, Decker JL Echocardiographic identification of cardiac abnormality in scleroderma and related disorders. Am J Med 1979, 66:391-398.
262. Di Bello V, Ferri C, Giorgi D, et al. Ultrasonic videodensitometric analysis in scleroderma heart disease. Coron Artery Dis 1999, 10:103-110.
263. Garty BZ, Athreya BH, Wilmott R, et al. Pulmonary functions in children with progressive systemic sclerosis. Pediatrics 1991, 88:1161-1167.
264. Falcini F, Pignone A, Matucci-Cerinic M, et al. Clinical utility of non invasive methods in the evaluation of scleroderma lung in pediatric age. Scand J Rheumatol 1992, 21:82-84.
265. Steen VD, Owens GR, Fino GJ, et al. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985, 28:759-767.
266. Guttadauria M, Ellman H, Kaplan D Progressive systemic sclerosis: Pulmonary involvement. Clin Rheum Dis 1979, 5:151.
267. Kovalchik MT, Guggenheim SJ, Silverman MH, et al. The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 1978, 89:881-887.
268. Szymanska-Jagiello W, Rondio H Clinical picture of articular changes in progressive systemic sclerosis in children in the light of own observations. Reumatologia 1970, 8:1-9.
269. Resnick D, Niwayama G Scleroderma (progressive systemic sclerosis). Diagnosis of Bone and Joint Disorders 1988, 1293. WB Saunders, Philadelphia. D. Resnick, G. Niwayama (Eds.).
270. Rowell BR, Hopper FF The periodontal membrane in systemic sclerosis. Br J Dermatol 1975, 93(Suppl 2):23.
271. Resnick D, Greenway G, Vint VC, et al. Selective involvement of the first carpometacarpal joint in scleroderma. AJR Am J Roentgenol 1978, 131:283-286.
272. Weber P, Ganser G, Frosch M, et al. Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol 2000, 27:2692-2695.
273. Martel W, Chang SF, Abell MR Loss of colonic haustration in progressive systemic sclerosis. Am J Roentgenol 1976, 126:704-713.
274. Seely JM, Jones LT, Wallace C, et al. Systemic sclerosis: using high-resolution CT to detect lung disease in children. AJR Am J Roentgenol 1998, 170:691-697.
275. Shahin AA, Sabri YY, Mostafa HA, et al. Pulmonary function tests, high-resolution computerized tomography, alpha1-antitrypsin measurement, and early detection of pulmonary involvement in patients with systemic sclerosis. Rheumatol Int 2001, 20:95-100.
276. Koh DM, Hansell DM Computed tomography of diffuse interstitial lung disease in children. Clin Radiol 2000, 55:659-667.
277. Heickendorff L, Zachariae H, Bjerring P, et al. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 1995, 32:584-588.
278. Hunzelmann N, Risteli J, Risteli L, et al. Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma?. Br J Dermatol 1998, 139:1020-1025.
279. Denton CP, Bickerstaff MC, Shiwen X, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995, 34:1048-1054.
280. Medsger TA Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000, 12:545-548.
281. Steen VD, Medsger TA The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997, 40:1984-1991.
282. Silman A, Akesson A, Newman J, et al. Assessment of Functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998, 25:79-83.
283. Della RA, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001, 60:585-591.
284. Valentini G, Delia RA, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001, 60:592-598.
285. Foeldvari I, Wulffraat N Recognition and management of scleroderma in children. Paediatr Drugs 2001, 3:575-583.
286. Steen VD, Lanz JK, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994, 37:1290-1296.
287. van den Hoogen, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996, 35:364-372.
288. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1351-1358.
289. Stratton RJ, Wilson H, Black CM Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxf) 2001, 40:84-88.
290. Steen VD, Medsger TA Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41:1613-1619.
291. Antoniades L, Sfikakis PP, Mavrikakis M Glucocorticoid effects on myocardial performance in patients with systemic sclerosis. Clin Exp Rheumatol 2001, 19:431-437.
292. Ellman MH, MacDonald PA, Hayes FA Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum 2000, 43(Suppl):S392.
293. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993, 36:75-83.
294. Filaci G, Cutolo M, Scudeletti M, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxf) 1999, 38:992-996.
295. Morton SJ, Powell RJ Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxf) 2000, 39:865-869.
296. Gisslinger H, Burghuber OC, Stacher G, et al. Efficacy of cyclosporin A in systemic sclerosis. Clin Exp Rheumatol 1991, 9:383-390.
297. Casoli P, Carretti C, Tumiati B Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal. Clin Rheumatol 1994, 13:126-128.
298. Wulffraat NM, Sanders LA, Kuis W Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2000, 2:316-323.
299. Farge D, Marolleau IP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002, 119:726-739.
300. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001, 60:577-584.
301. Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum 1999, 42:807-811.
302. Steen VD, Medsger TA, Rodnan GP D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982, 97:652-659.
303. Jimenez SA, Sigal SH A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991, 18:1496-1503.
304. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999, 42:1194-1203.
305. Furst DE, Clements PJ D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 2001, 30:189-191.
306. Medsger TA, Lucas M, Wildy KS, et al. d-Penicillamine in systemic sclerosis?. Yes! Scand J Rheumatol 2001, 30:192-194.
307. Steigerwald JC Colchicine vs. placebo in the treatment of progressive systemic sclerosis. Systemic Sclerosis (Scleroderma) 1985, 415. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
308. Alarcon-Segovia D, Ramos-Niembro F, Ibanez DK, et al. Long-term evaluation of colchicine in the treatment of scleroderma. J Rheumatol 1979, 6:705-712.
309. Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999, 42:299-305.
310. Grassegger A, Schuler G, Hessenberger G, et al. lnterferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998, 139:639-648.
311. Unemori EN, Pickford LB, Salles AL, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung Fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996, 98:2739-2745.
312. Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000, 132:871-879.
313. Smith CD, McKendry RJ Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet 1982, 2:1299-1301.
314. Rodeheffer RJ, Rommer JA, Wigley F, et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983, 308:880-883.
315. Sauza J, Kraus A, Gonzalez-Amaro R, et al. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial. J Rheumatol 1984, 11:362-364.
316. Winston EL, Pariser KM, Miller KB, et al. Nifedipine as a therapeutic modality for Raynaud's phenomenon. Arthritis Rheum 1983, 26:1177-1180.
317. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646-2655.
318. Kontos HA, Wasserman AJ Effect of reserpine in Raynaud's phenomenon. Circulation 1969, 39:259-266.
319. Varadi DP, Lawrence AM Suppression of Raynaud's phenomenon by methyldopa. Arch Intern Med 1969, 124:13-18.
320. McFadyen IJ, Housley E, MacPherson AI Intraarterial reserpine administration in Raynaud syndrome. Arch Intern Med 1973, 132:526-528.
321. Miyazaki S, Miura K, Kasai Y, et al. Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon. Br Med J (Clin Res Ed) 1982, 284:310-311.
322. Seibold JR, Jageneau AH Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis Rheum 1984, 27:139-146.
323. Coffman JD, Clement DL, Creager MA, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989, 87:264-268.
324. Naidoo P Griseofulvin in Raynaud's phenomenon. Lancet 1971, 2:1090.
325. Martin MF, Dowd PM, Ring EF, et al. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981, 40:350-354.
326. Belch JJ, McKay A, McArdle B, et al. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet 1983, 1:315-317.
327. Giordano M, Ara M, Capelli L, et al. Griseofulvin in scleroderma. Systemic Sclerosis (Scleroderma) 1985, 446-448. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
328. Drake DB, Kesler RW, Morgan RF Digiial sympathectomy for refractory Raynaud's phenomenon in an adolescent. J Rheumatol 1992, 19:1286-1288.
329. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994, 120:199-206.
330. Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxf) 2004, 43:229-233.
331. Black CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998, 37:952-960.
332. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998, 41:670-677.
333. Russell IJ, Lessard JA Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. J Rheumatol 1985, 12:94-98.
334. Coppock JS, Hardman JM, Bacon PA, et al. Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud's phenomenon. Postgrad Med J 1986, 62:15-18.
335. Talpos G, Horrocks M, White JM, et al. Plasmapheresis in Raynaud's disease. Lancet 1978, 1:416-417.
336. Winkelmann RK, McCune MA, Pineda AA, et al. A controlled study of plasma exchange in scleroderma. Systemic Sclerosis (Scleroderma) 1985, 449-453. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
337. Surwit RS Biofeedback: a possible treatment for Raynaud's disease. Semin Psychiatry 1973, 5:483-490.
338. Beckett VL, Donadio JV, Brennan LA, et al. Use of captopril as early therapy for renal scleroderma: a prospective study. Mayo Clin Proc 1985, 60:763-771.
339. Whitman HH III, Case DB, LeRoy EC Management of hypertensive scleroderma patients with converting-enzyme inhibition. Systemic Sclerosis (Scleroderma) 1985, 428. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
340. Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990, 113:352-357.
341. Maddison P Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology (Oxf) 2002, 41:965-971.
342. Richardson JA Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum 1973, 16:265-271.
343. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
344. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003, 167:580-586.
345. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302.
346. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
347. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
348. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136:515-522.
349. Kinuya K, Nakajima K, Kinuya S, et al. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 2001, 15:97-101.
350. Bottoni CR, Reinker KA, Gardner RD, et al. Scleroderma in childhood: a 35-year history of cases and review of the literature. J Pediatr Orthop 2000, 20:442-449.
351. Hochberg MC, Lopez-Acuna D, Gittelsohn AM Mortality from systemic sclerosis (scleroderma) in the United States, 1969-1977. Systemic Sclerosis (Scleroderma) 1985, 61. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
352. Foeldvari I, Zhavania M, Birdi N, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxf) 2000, 39:556-559.
353. Bulkley BH, Ridolfi RL, Salyer WR, et al. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976, 53:483-490.
354. Silman AJ Pregnancy and scleroderma. Am J Reprod Immunol 1992, 28:238-240.
355. Buyon JP The effects of pregnancy on autoimmune diseases. J Leukoc Biol 1998, 63:281-287.
356. Jacobsen S, Halberg P, Ullman S Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998, 37:750-755.
357. Simeon CP, Armadans L, Fonollosa V, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997, 56:723-728.
358. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993, 118:602-609.
359. Winlerbauer RH Multiple telangiectasia. Raynaud's phenomenon, sclerodactyly and subcutaneous calcinosis: A syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp 1964, 114:361.
360. Fritzler MJ, Kinsella TD The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980, 69:520-526.
361. Thibierge G, Wiessenbach RJ Concretions calcaires souscutanees et sclerodermie. Ann Dermatol Syph 1911, 2:129.
362. Rodnan GP, Jablonska S Classification of systemic and localized scleroderma. Systemic Sclerosis (Scleroderma) 1985, 3. Gower Medical, New York. C.M. Black, A.R. Myers (Eds.).
363. Tan EM, Rodnan GP, Garcia I, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980, 23:617-625.
364. Powell FC, Winkelmann RK, Venencie-Lemarchand F, et al. The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 1984, 59:700-706.
365. Furst DE, Clements PJ, Saab M, et al. Clinical and serological comparison of 17 chronic progressive systemic sclerosis (PSS) and 17 CREST syndrome patients matched for sex, age, and disease duration. Ann Rheum Dis 1984, 43:794-801.
366. Sato S, Komura K, Hasegawa M, et al. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc. J Rheumatol 2001, 28:2460-2465.
367. Maricq HR, LeRoy EC, D'Angelo WA, et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980, 23:183-189.
368. Maricq HR Wide-field capillary microscopy. Arthritis Rheum 1981, 24:1159-1165.
369. Coffman JD Drug therapy: vasodilator drugs in peripheral vascular disease. N Engl J Med 1979, 300:713-717.
370. Gifford RW The arteriospastic diseases: clinical significance and management. Cardiovasc Clin 1971, 3:127-139.
371. Hansteen V, Lorentsen E Vasodilator drugs in the treatment of peripheral arterial insufficiency. Acta Med Scand Suppl 1974, 556:3-62.